Skip to main content
. 2011 Oct 21;6(10):e26688. doi: 10.1371/journal.pone.0026688

Figure 6. The role of the peripheral nitric oxide–cGMP–PKG-KATP signaling pathway in the antinociceptive effects of JWH-015.

Figure 6

Mechanical antiallodynic (A, C, E) and thermal antihyperalgesic (B, D, F) effects of the subplantar co-administration of JWH-015 (150 µg) plus vehicle or different doses of ODQ (0.3 – 3.0 µg; A, B), Rp-8-pCPT-cGMPs (Rp-8; 0.3-5.0 µg; C, D) or glibenclamide (GC; 3.0–10 µg; E,F) in the ipsilateral paw of WT mice at 10 days after CFA injection. The effects of the subplantar administration of vehicle and the maximal doses of ODQ (3.0 µg), Rp-8 (5.0 µg) or glibenclamide (10.0 µg) administered alone are also shown. All drugs were administered 20 min before starting behavioral testing. Data are expressed as mean values of the von Frey filaments strength (g) for mechanical allodynia and as the paw withdrawal latency (s) for thermal hyperalgesia ± SEM (5–6 animals per group). For each behavioral test and selective inhibitor assayed, * p<0.05 denotes significant differences vs. group treated with JWH-015 + vehicle (one way ANOVA followed by Student Newman Keuls test).